Specifically, SRSF9 and SND1 have been found overexpressed in several tumor pathologies, such as breast cancer, bladder cancer, glioblastoma, melanoma, or hepatocellular carcinoma, where they have been associated with an increase in cell proliferation, invasion and poor prognosis [47,48,49,50,51]. Here, SRSF9 is linked to breast cancer.